コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 m-relebactam (an investigational beta-lactam/beta-lactamase inhibitor).
2 the co-administration of an antibiotic and a beta-lactamase inhibitor.
3 nactivated with tazobactam, a potent class A beta-lactamase inhibitor.
4 ncoding production of the antibiotic and the beta-lactamase inhibitor.
5 pectrum of inhibition than any other current beta-lactamase inhibitor.
6 orally bioavailable diazabicyclooctane (DBO) beta-lactamase inhibitor.
7 tam), a boronic-acid-containing pan-spectrum beta-lactamase inhibitor.
8 dependent upon or enhanced by clavulanate, a beta-lactamase inhibitor.
9 e rational design of mechanism-based class A beta-lactamase inhibitors.
10 ey show promise as leads to specific class D beta-lactamase inhibitors.
11 t bacteria and escape the action of existing beta-lactamase inhibitors.
12 have been prepared as a potential source of beta-lactamase inhibitors.
13 an intriguing new platform for the design of beta-lactamase inhibitors.
14 n aid the design of improved mechanism-based beta-lactamase inhibitors.
15 nd have implications for the design of novel beta-lactamase inhibitors.
16 nity of the active site for beta-lactams and beta-lactamase inhibitors.
17 library (DECL) technology to discover novel beta-lactamase inhibitors.
18 eta-lactam antibiotics and combinations with beta-lactamase inhibitors.
19 al hotspot and might aid the design of novel beta-lactamase inhibitors.
20 lactam antibiotics in a manner distinct from beta-lactamase inhibitors.
21 mechanism distinct from that of traditional beta-lactamase inhibitors.
22 present one of the most promising classes of beta-lactamase inhibitors.
23 t)/k(inact) values of 2000, 1500, and 75 for beta-lactamase inhibitors.
24 e that exhibits resistance to most available beta-lactamase inhibitors.
25 ch is a unique mechanism of inhibition among beta-lactamase inhibitors.
26 with carbapenemase activity are resistant to beta-lactamase inhibitors.
27 ities and challenges to the search for novel beta-lactamase inhibitors.
28 terial siderophore, LN-1-255 is unique among beta-lactamase inhibitors.
29 m cephalosporins or to avoid inactivation by beta-lactamase inhibitors.
30 , we evaluated the diagnostic utility of the beta-lactamase inhibitors 48-1220 (Ro 48-1220) and LN-2-
31 the benzhydryl ester of the mechanism-based beta-lactamase inhibitor, 7-[(2'-pyridyl)methylidene]-ce
33 erly AAI101) is a novel penicillanic sulfone beta-lactamase inhibitor active against a wide range of
35 provide insights for the development of new beta-lactamase inhibitors against these critical drug re
36 ylpenicillin MIC >= 256 mug/ml), beta-lactam/beta-lactamase inhibitors and cephalosporins (amoxicilli
37 These approaches include the development of beta-lactamase inhibitors and compounds that interfere w
38 lization has generated a renewed interest in beta-lactamase inhibitors and improved the prospects for
39 An overview of the most recently identified beta-lactamase inhibitors and of combination therapy is
41 methoxazole, colistin, and novel beta-lactam/beta-lactamase inhibitors) and resistance spread (trimet
42 , and combinations of penicillins, including beta-lactamase inhibitors) and two had a known interacti
43 he synthesis of new beta-lactam antibiotics, beta-lactamase inhibitors, and bicyclic carbohydrate-bet
44 d, evaluated as serine (classes A, C, and D) beta-lactamase inhibitors, and compared with respect to
45 including green fluorescent proteins (GFPs), beta-lactamase inhibitors, and nuclear receptors, and we
46 zabicyclooctanone and cyclic boronate serine beta-lactamase inhibitors, and of progress and strategie
48 lass, such as meropenem, with clavulanate, a beta-lactamase inhibitor, are being evaluated for the tr
49 complex with avibactam, a diazabicyclooctane beta-lactamase inhibitor at 1.6-2.0 angstrom resolution.
50 with ceftazidime, the novel non-beta-lactam beta-lactamase inhibitor avibactam provides a carbapenem
51 ay crystallography and the recently approved beta-lactamase inhibitor avibactam to trap the acyl-enzy
52 c inhibitors, such as the derivatives of the beta-lactamase inhibitor avibactam, are closer to the cl
55 entify susceptibility to 2 newer beta-lactam/beta-lactamase inhibitor (BL-BLI) combinations, ceftazid
56 penem-relebactam (IMR) are newer beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations used for
58 nzymes, combinations of a beta-lactam with a beta-lactamase inhibitor (BLI) have been clinically succ
61 reacylation complex of sulbactam, a clinical beta-lactamase inhibitor, bound in the active site of th
62 ituation now dictates that second-generation beta-lactamase inhibitors capable of encompassing both c
63 any antibiotic exposure; classes beta-lactam-beta-lactamase inhibitors, carbapenem, cephalosporin, fl
64 of Mycobacterium tuberculosis (Mtb) with the beta-lactamase inhibitor clavulanate together with merop
67 o most cephalosporins, beta-lactams, and the beta-lactamase inhibitor clavulanic acid as well as resi
71 130 confer resistance to inactivation by the beta-lactamase inhibitors, clavulanic acid, and tazobact
73 fepime/enmetazobactam is a novel beta-lactam/beta-lactamase inhibitor combination and a potential emp
74 enem-vaborbactam (MEV) is a novel carbapenem-beta-lactamase inhibitor combination antibiotic approved
76 ce to important broad-spectrum cephalosporin/beta-lactamase inhibitor combination antibiotics through
81 peracillin-tazobactam (P/T) is a beta-lactam-beta-lactamase inhibitor combination frequently used in
82 rlobactam is a pathogen-targeted beta-lactam/beta-lactamase inhibitor combination in late-stage devel
83 e), a monocyclic beta-lactam (BAL30072), the beta-lactamase inhibitor combination of tazobactam with
84 tolozane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor combination that often retains
86 nce to ampicillin/clavulanate, a beta-lactam/beta-lactamase inhibitor combination used to treat serio
87 bactam is an investigational beta-lactam and beta-lactamase inhibitor combination with activity again
88 ctam-durlobactam, a unique beta-lactam and a beta-lactamase inhibitor combination, is a novel agent t
89 analyzed, including penicillins, penicillin/beta lactamase inhibitor combinations, and sulfonamides.
90 an emerging threat to the use of beta-lactam/beta-lactamase inhibitor combinations (e.g. amoxicillin/
92 ies suggested that resistance to beta-lactam-beta-lactamase inhibitor combinations conferred by pLRM7
94 eftaroline, ertapenem, and novel beta-lactam-beta-lactamase inhibitor combinations from January 2017
95 ndings should not be extended to beta-lactam/beta-lactamase inhibitor combinations in development, as
96 nded-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations is achievable via
97 y with respect to empirical therapy with new beta-lactamase inhibitor combinations such as ceftazidim
98 display cryptic susceptibility to penicillin/beta-lactamase inhibitor combinations under in vitro con
106 initiated to discover a new series of serine beta-lactamase inhibitors containing a boronic acid phar
108 that a combination of L,D-transpeptidase and beta-lactamase inhibitors could effectively target persi
109 fective against the TEM and P99 enzymes; the beta-lactamase inhibitors currently employed in medical
110 Durlobactam, a novel diazabicyclooctane beta-lactamase inhibitor, demonstrated minimum inhibitor
112 ediate" analogue approach for broad-spectrum beta-lactamase inhibitor development and highlight the a
114 iew is provided of the changing landscape of beta-lactamase inhibitors, exemplified by the introducti
118 has important implications in the design of beta-lactamase inhibitors for drug resistant variants li
119 lactam pharmacophores for the development of beta-lactamase inhibitors for enzymes of different struc
120 tive drugs to carbapenems except beta-lactam/beta-lactamase inhibitors for the treatment of bloodstre
122 tion of extended-spectrum cephalosporins and beta-lactamase inhibitors has driven the evolution of ex
126 ere to guide the creation of two novel short beta-lactamase inhibitors, here named dBLIP-1 and -2, wi
127 more susceptible to inactivation by sulfone beta-lactamase inhibitors (i.e., sulbactam and tazobacta
129 incipal bacterial resistance mechanisms: (i) beta-lactamase inhibitors; (ii) outer membrane permeabil
130 and avibactam are clinically deployed serine beta-lactamase inhibitors, important as a defence agains
134 ms, whereas newer drug classes include novel beta-lactamase inhibitors in combination with new or app
136 resistant to combinations of beta-lactam and beta-lactamase inhibitors is creating great difficulties
139 f inhibition of these enzymes by therapeutic beta-lactamase inhibitors is probed using a novel approa
140 rd clavulanic acid, the clinically important beta-lactamase inhibitor, is catalyzed by the thiamin di
144 derivatives as a new class of potent metallo-beta-lactamase inhibitors (MBLIs) by applying scaffold h
145 ed a knowledge-based search of known metallo-beta-lactamase inhibitors (MBLIs) to identify starting p
147 posure to combinations of penicillins with a beta-lactamase inhibitor (minimum HR among models, 6.55;
148 d in the final deprotection/isolation of the beta-lactamase inhibitor MK-7655 as a part of its manufa
149 ephalosporins, fluoroquinolones, beta-lactam/beta-lactamase inhibitors, multidrug resistant strains a
152 the monobactam aztreonam and BAL29880, a new beta-lactamase inhibitor of the monobactam class, inacti
153 H, was reported as a low cytotoxic nanomolar beta-lactamase inhibitor of Verona-integron-encoded meta
154 ztreonam-like beta-lactams plus nonclassical beta-lactamase inhibitors, particularly avibactam-like a
155 switch sensor consists of a beta-lactamase - beta-lactamase inhibitor protein (BLA-BLIP) complex with
160 lactam agents including agents paired with a beta-lactamase inhibitor (r >/= 0.87) and for ciprofloxa
163 organism to amoxicillin, by repurposing the beta-lactamase inhibitor, relebactam, in combination wit
164 determine the molecular factors that lead to beta-lactamase inhibitor resistance for the M69V variant
166 and specific classes monobactam, beta-lactam-beta-lactamase inhibitors, rifamycin, and cephalosporin.
167 CI, 1.15-2.37]) and exposure to beta-lactams/beta-lactamase inhibitors (risk ratio, 1.78 [95% CI, 1.2
170 lved phenotypic tests, isoelectric focusing, beta-lactamase inhibitor studies, spectrophotometric ass
173 rial response to the clinical use of class A beta-lactamase inhibitors such as tazobactam and clavula
174 he high resolution crystal structures of the beta-lactamase inhibitors sulbactam and clavulanic acid
176 he enzyme's inhibition by three FDA-approved beta-lactamase inhibitors: sulbactam, tazobactam, and cl
177 moth and mouse models shows that penicillin/beta-lactamase inhibitor susceptibility can be exploited
178 antibacterial combination consisting of the beta-lactamase inhibitor tazobactam and a fourth-generat
179 actam is a first-generation, narrow-spectrum beta-lactamase inhibitor that also has intrinsic antibac
182 to guide derivatization of a lead series of beta-lactamase inhibitors that had heretofore resisted o
183 characterization of expanded-spectrum serine beta-lactamase inhibitors that potently inhibit clinical
184 be exploited in developing antibiotics, and beta-lactamase inhibitors, that form long-lasting comple
185 coproduction of beta-lactam antibiotics and beta-lactamase inhibitors, the coproduction of type A an
186 despread clinical use as part of beta-lactam beta-lactamase inhibitor therapy directed against penici
187 tics and antibiotic adjuvants, such as novel beta-lactamase inhibitors, these organisms continue to r
189 is generating an interest in developing new beta-lactamase inhibitors to complement currently availa
190 ts, including penicillins, cephalosporins, a beta-lactamase inhibitor, vancomycin, erythromycin, tetr
191 aining 10 beta-lactam drugs with and without beta-lactamase inhibitors was developed to identify beta
193 1, discovered earlier as B. fragilis metallo-beta-lactamase inhibitors, was selected for in silico vi
194 an effort to identify non-beta-lactam-based beta-lactamase inhibitors, we used the crystallographic
196 se, and tazobactam, a commercially available beta-lactamase inhibitor, were rapidly mixed on the mill
197 ombination of a beta-lactam antibiotic and a beta-lactamase inhibitor, which, on the basis of the mic
200 methoxazole-trimethoprim, or beta-lactam and beta-lactamase inhibitor with or without a macrolide) ha
202 usly VNRX-5133) is a novel bicyclic boronate beta-lactamase inhibitor with potent, selective, and dir
203 a member of the diazabicyclooctane class of beta-lactamase inhibitors with broad-spectrum serine bet
204 activities of sulbactam and two novel penem beta-lactamase inhibitors with sp2 hybridized C3 carboxy